Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Lynn Mara Schuchter, M.D.

Lynn Mara Schuchter, M.D.

faculty photo
C. Willard Robinson Professor of Hematology-Oncology
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
South Pavilion, 6th Floor, Room 631
Philadelphia, PA 19104
Office: 215-662-4859
Fax: 215-349-5866
Education:
B.S.
University of Michigan, 1978.
M.D.
Chicago Medical School, 1982.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Selected Publications

Amaravadi RK, Hamilton KE, Ma X, Piao S, Del Portillo A, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JD, Tsai KY, Flaherty KT, Sosman J, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Seuplveda AR: Multiple gastrointestinal polyps in patients treated with BRAF inhibitors. Clin Cancer Res. July 2015.

Gangadhar TC, Schuchter LM. : Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status. JAMA Oncol. 1(4): 427-8, Jul 1 2015.

Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher M, Chen H, Sehgal C, O'Dwyer PJ. : Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. Oncologist Jun 17 2015.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547): 373-7, Apr 16 2015.

Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis G, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn M, Kaufman RE: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res 21(7): 1652-64, Apr 1 2015.

Weber JS, Levit LA, Adamson PC, Bruinooge S, Burris HA 4th, Carducci MA, Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM: American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol 33(3), Jan 20 2015.

Weber JS, Levit LA, Adamson PC, Bruinooge S, Burris HA Iiii, Carducci MA, Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM: American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. J Clin Oncol Dec 2014.

Glanz K, Volpicelli K, Jepson C, Ming ME, Schuchter LM, Armstrong K. : Effects of Tailored Risk Communications for Skin Cancer Prevention and Detection: The PennSCAPE Randomized Trial. Cancer Epidemiol Biomarkers Prev 24(2), Nov 2014.

Lam L, Czerniecki BJ, Fitzpatrick E, Xu S, Schuchter L, Xu X, Zhang H. : Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer. J Mol Biomark Diagn Nov 2014.

Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. : Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 32(33): 3697-704, Nov 2014.

back to top
Last updated: 07/31/2015
The Trustees of the University of Pennsylvania